US equities
|
SPCX
$166.89
▲+4.99%
NVDA
$236.81
▲+1.22%
MU
$1,064.30
▼-0.99%
TSLA
$377.20
▲+1.78%
MSFT
$525.40
▲+1.52%
SNDK
$1,708.01
▼-0.70%
INTC
$117.28
▼-1.72%
META
$743.05
▲+2.06%
SPCX
$166.89
▲+4.99%
NVDA
$236.81
▲+1.22%
MU
$1,064.30
▼-0.99%
TSLA
$377.20
▲+1.78%
MSFT
$525.40
▲+1.52%
SNDK
$1,708.01
▼-0.70%
INTC
$117.28
▼-1.72%
META
$743.05
▲+2.06%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Exelixis, Inc.
< Previous
1
2
3
4
5
6
Next >
Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 Trial
October 04, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022
September 10, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022
September 07, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in September
September 06, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Second Quarter 2022 Financial Results and Provides Corporate Update
August 09, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
July 26, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer
July 11, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies
July 07, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference
July 05, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer
June 21, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies
June 16, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in June
May 31, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022
May 26, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022
May 26, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update
May 10, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in May
May 04, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
May 03, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022
April 26, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma
April 14, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Charles Cohen, Ph.D., to Retire from Board of Directors
April 13, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
March 25, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer
March 14, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
February 17, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 17, 2022
February 03, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Webcast Virtual Fireside Chat as Part of the Guggenheim Healthcare Talks Oncology Day on February 9, 2022
February 02, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022
January 18, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022
January 09, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor
January 06, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma
January 05, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022
January 04, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
< Previous
1
2
3
4
5
6
Next >
